RT Journal Article
T1 Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients.
A1 Villanego, Florentino
A1 Mazuecos, Auxiliadora
A1 Cubillo, Beatriz
A1 Merino, M José
A1 Poveda, Inmaculada
A1 Saura, Isabel M
A1 Segurado, Óscar
A1 Cruzado, Leónidas
A1 Eady, Myriam
A1 Zárraga, Sofía
A1 Aladrén, M José
A1 Cabello, Sheila
A1 López, Verónica
A1 González, Esther
A1 Lorenzo, Inmaculada
A1 Espí-Reig, Jordi
A1 Fernández, Constantino
A1 Osma, July
A1 Ruiz-Fuentes, M Carmen
A1 Toapanta, Néstor
A1 Franco, Antonio
A1 Burballa, Carla C
A1 Muñoz, Miguel A
A1 Crespo, Marta
A1 Pascual, Julio
K1 COVID-19
K1 immunosuppression
K1 kidney transplantation
K1 monoclonal antibodies
K1 mortality
AB Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. We performed a multicenter, retrospective cohort study of 82 KT patients with SARS-CoV-2 infection {coronavirus disease 2019 [COVID-19]} treated with sotrovimab. Median age was 63 years. Diabetes was present in 43.9% of patients, and obesity in 32.9% of patients; 48.8% of patients had an estimated glomerular filtration rate under 30 mL/minute/1.73 m2. Additional anti-COVID-19 therapies were administered to 56 patients, especially intravenous steroids (65.9%). Sotrovimab was administered early ( Sotrovimab had an excellent safety profile, even in high-comorbidity patients and advanced chronic kidney disease stages. Earlier administration could prevent progression to severe disease, while clinical outcomes were poor in patients treated later. Larger controlled studies enrolling KT recipients are warranted to elucidate the true efficacy of monoclonal antibody therapies.
SN 2048-8505
YR 2022
FD 2022-07-28
LK http://hdl.handle.net/10668/19754
UL http://hdl.handle.net/10668/19754
LA en
DS RISalud
RD Apr 11, 2025